Early data suggest that mezigdomide, an oral cereblon‑targeting agent, could become a new option for patients whose multiple myeloma has returned or stopped responding to existing therapies.
Clinical trial shows longer remission with mezigdomide combo
At the 2026 American Society of Clinical Oncology meeting, investigators from the Dana‑Farber Cancer Institute reported results from the phase 3 SUCCESSOR‑2 trial. The study compared a three‑drug regimen of mezigdomide, carfilzomib and dexamethasone (MeziKd) with the standard two‑drug combination of carfilzomib and dexamethasone (Kd) in people with relapsed or refractory multiple myeloma (RRMM).
Patients receiving MeziKd experienced a statistically significant extension of progression‑free survival, meaning their disease stayed stable for a longer period before worsening. The trial also recorded higher overall response rates, including a greater proportion of deep responses where tumor burden fell dramatically.
Related: New hope in lung cancer treatment
How mezigdomide differs from existing treatments
Mezigdomide belongs to a newer class called cereblon E3 ligase modulatory drugs (CELMoDs). Like the long‑standing immunomodulatory drug lenalidomide (Revlimid), it binds to the protein cereblon, triggering degradation of proteins that myeloma cells need to survive. However, laboratory studies indicate that mezigdomide attaches more tightly to cereblon, potentially increasing its ability to eliminate cancer cells even when disease burden is low.
Dr. Brandon Blue, a hematologist/oncologist at Moffitt Cancer Center, likened the mechanism to a stronger “nose” for detecting cancer. “If the drug is sniffing out cancer so it can find it and kill it, mezigdomide has a much stronger nose,” he said, adding that the agent may detect residual disease that lenalidomide cannot.
Because CELMoDs are designed to retain activity when earlier immunomodulatory drugs lose effectiveness, they provide a backup option for patients whose disease has become resistant to lenalidomide.
Patients need close monitoring.
Related: Counseling eases stress before it grows
Safety considerations and patient monitoring
Like other myeloma agents, mezigdomide can suppress bone marrow function, most notably causing neutropenia—a reduction in white blood cells that raises infection risk. Dr. Blue warned that “the biggest side effect is low blood counts,” emphasizing the importance of early detection of fever or chills and prompt communication with the care team.
Clinicians may employ prophylactic antibiotics or adjust dosing to mitigate infection risk. Patients are advised to remain vigilant for signs of infection and to follow supportive care guidelines closely.
While the initial results are encouraging, it is prudent to temper optimism with the reality that the SUCCESSOR‑2 trial involved a specific patient population and that longer‑term outcomes are still being tracked. The current evidence base, though promising, is not yet sufficient to define the full role of mezigdomide in multiple myeloma treatment.
Leave a Reply